XML 24 R18.htm IDEA: XBRL DOCUMENT
v3.24.3

Employee Benefits | 9 Months Ended
--- | ---
Sep. 30, 2024
Retirement Benefits [Abstract] |
Employee Benefits | 10. Employee Benefits Share-Based Compensation Share-based compensation expense is classified in the condensed consolidated statements of operations and comprehensive loss as follows:
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2024 |  |  | 2023 |  |  | 2024 |  |  | 2023 |
|  | (in thousands) |  |  | (in thousands) |
Research and development |  | $ | 7,166 |  |  | $ | 2,959 |  |  | $ | 14,281 |  |  | $ | 8,859 |
General and administrative |  |  | 6,326 |  |  |  | 4,356 |  |  |  | 15,690 |  |  |  | 10,659 |
Total |  | $ | 13,492 |  |  | $ | 7,315 |  |  | $ | 29,971 |  |  | $ | 19,518 |
The weighted-average grant date fair value of options, estimated as of the grant date using the Black Scholes option pricing model was $25.01 per option for the 2,954,935 options granted during the nine months ended September 30, 2024. The following assumptions were used to estimate the fair value of the options granted during the nine months ended September 30, 2024.
Volatility |  | 67.6 | %
Risk-free interest rate |  | 4.4 | %
Expected holding period (in years) |  | 6.2 |
Dividend yield |  | - |
Contingent Share Option Awards On February 1, 2024, the Board of Directors approved the grant of share options to purchase 2,446,045 common shares, at an exercise price of $36.09 per share, to employees as the annual grant for 2024. These share option grants were approved subject to Company's general meeting resolving upon, and the Board of Directors having implemented through an amendment to the Company's articles of association, an increase in the authorized share capital sufficient to satisfy the award set forth in the resolution (such shareholder resolution to be proposed to the Company's annual general meeting to be held in 2024) (the “Shareholder Approval Condition”), provided that such options will be forfeited if the Shareholder Approval Condition is not satisfied ultimately by January 1, 2025. On May 7, 2024, the shareholders approved the amendment to the Company’s articles of association, including the requisite increase in the authorized share capital satisfying the Shareholder Approval Condition, therefore the grant-date fair value of the contingent shares is based on the Black-Scholes valuation model based on the fair market value of the share on the shareholder approval date. Share-based compensation expense was recorded beginning in the second quarter of 2024 relating to these contingent share option awards.

X
- Definition The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 710 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/710/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 712 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/712/tableOfContent Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 715 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/715/tableOfContent Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent + Details
Name: | us-gaap_CompensationAndEmployeeBenefitPlansTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_CompensationAndRetirementDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration